Mode
Text Size
Log in / Sign up
Phase 4 N=121 Basic Science

Emotional and Cognitive Control in Late-Onset Depression

Depression

Enrolled (actual)
121
Serious AEs
1.7%
Results posted
Oct 2020
Primary outcome: Primary: Change in Depression Severity (Measured by Montgomery Asberg Depression Rating Scale) — 25.26; 1.03; 13.78; 1.08 score on a scale — p=< 0.025

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Escitalopram (Drug); Magnetic Resonance Imaging (Other)
Age
Adult, Older Adult · 60+ yrs
Sex
All
Sponsor
Weill Medical College of Cornell University
Primary completion
Jul 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Depression Severity (Measured by Montgomery Asberg Depression Rating Scale)
25.26; 1.03; 13.78; 1.08 < 0.025 sig
SECONDARY
Change in Depression Severity (Measured by Hamilton Depression Rating Scale)
23.48; 1.24; 12.44; 1.52 <0.025 sig

Summary

This study may help identify how abnormalities in brain systems that control the ability to ignore irrelevant information may contribute to the development of depression in older adults.

Eligibility Criteria

Inclusion Criteria

  • Age: 60-85 years, right-handed;
  • Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria);
  • Age of onset of first episode ≥ 50 years with up to three depressive episodes;
  • Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) ≥ 20.

Exclusion Criteria

  • Psychotic depression by DSM-IV, i.e., presence of delusions with a SCID-R score higher than 2;
  • High suicide risk, i.e. intent or plan to attempt suicide in near future;
  • Presence of any Axis I psychiatric disorder (other than unipolar major depression) or substance abuse;
  • History of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (bipolar disorder, hypomania, and dysthymia are exclusion criteria);
  • Dementia: Diagnosis of dementia by DSM-IV;
  • Mild Cognitive Impairment (MCI);
  • Acute or severe medical illness, i.e., delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or use of drugs known to cause depression, e.g., reserpine, alpha-methyl-dopa, steroids, sympathomimetics withdrawal;
  • Neurological brain disease and/or history of electroconvulsive therapy;
  • History of any use of citalopram or escitalopram during the current episode or need for drugs that may interact with these agents, i.e. drug metabolized by the 2D6 P450 isoenzyme system;
  • Current involvement in psychotherapy;
  • Contraindications to MRI scanning including cardiac pacemaker, metallic objects and metallic implants contraindicating MRI, cardiac stent, claustrophobia;
  • Inability to speak English;
  • Corrected visual acuity < 20/70; Color blindness.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01728194). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search